Developer site: The content shown here is test data.

Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Back to skin conditions

Sheehan's syndrome medical therapy

Introduction

Overview

Overview

Treatment involves appropriate hormone replacement therapy that results in complete recovery and reversal of symptoms.

Medical Therapy

Medical Therapy

ACTH deficiency

Acute setting

  • Preferred regimen: Hydrocortisone 100 mg IV bolus, then 300 mg/day IV divided q8hr or continuous infusion for 48 hours
    • Once patient is stable: 50 mg PO q8hr for 6 doses, later on tapered to 30-50 mg/day PO in divided doses

Chronic setting

NOTE

TSH deficiency

Mild hypothyroidism

Severe hypothyroidism

  • Levothyroxine 12.5-25 mcg PO qDay and later on dose can be adjusted by 25 mcg/day q2-4 Week PRN

NOTE

LH and FSH deficiency

Androgen replacement

Growth hormone replacement

  • GH is replaced on case to case basis starting with a low dose (0.1-0.3 mg/day) and titrated upwards by 0.1 mg/d/month with repeated measurement of hormone levels every month, initially for the first 6 months followed by yearly measurements; replaced once all other hormones have been replaced.[17]

Prolactin deficiency

  • A study was done on 5 women with prolactin deficiency caused by Sheehan’s syndrome or other causes that showed increased milk production upon subcutaneous administration of r-hPRL (recombinant human prolactin) every 12 hours for 28 days.[18]
References

References

  1. ↑ Parikh R, Buch V, Makwana M, Buch HN (2016). “The price of a 15-year delay in diagnosis of Sheehan’s syndrome”. Proc (Bayl Univ Med Cent). 29 (2): 212–3. PMCΒ 4790577. PMIDΒ 27034575.
  2. ↑ Laway BA, Bhat JR, Mir SA, Khan RS, Lone MI, Zargar AH (2010). “Sheehan’s syndrome with pancytopenia–complete recovery after hormone replacement (case series with review)”. Ann. Hematol. 89 (3): 305–8. doi:10.1007/s00277-009-0804-9. PMIDΒ 19697029.
  3. ↑ Tanriverdi F, Unluhizarci K, Kula M, Guven M, Bayram F, Kelestimur F (2005). “Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan’s syndrome”. Growth Horm. IGF Res. 15 (3): 231–7. doi:10.1016/j.ghir.2005.03.005. PMIDΒ 15921942.
  4. ↑ BΓΌlow B, Hagmar L, Mikoczy Z, NordstrΓΆm CH, Erfurth EM (1997). “Increased cerebrovascular mortality in patients with hypopituitarism”. Clin. Endocrinol. (Oxf). 46 (1): 75–81. PMIDΒ 9059561.
  5. ↑ Arafah BM (2002). “Medical management of hypopituitarism in patients with pituitary adenomas”. Pituitary. 5 (2): 109–17. PMIDΒ 12675508.
  6. ↑ Grossman AB (2010). “Clinical Review#: The diagnosis and management of central hypoadrenalism”. J. Clin. Endocrinol. Metab. 95 (11): 4855–63. doi:10.1210/jc.2010-0982. PMIDΒ 20719838.
  7. ↑ Esteban NV, Loughlin T, Yergey AL, Zawadzki JK, Booth JD, Winterer JC, Loriaux DL (1991). “Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry”. J. Clin. Endocrinol. Metab. 72 (1): 39–45. doi:10.1210/jcem-72-1-39. PMIDΒ 1986026.
  8. ↑ Arlt W, Rosenthal C, Hahner S, Allolio B (2006). “Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements”. Clin. Endocrinol. (Oxf). 64 (4): 384–9. doi:10.1111/j.1365-2265.2006.02473.x. PMIDΒ 16584509.
  9. ↑ Thomson AH, Devers MC, Wallace AM, Grant D, Campbell K, Freel M, Connell JM (2007). “Variability in hydrocortisone plasma and saliva pharmacokinetics following intravenous and oral administration to patients with adrenal insufficiency”. Clin. Endocrinol. (Oxf). 66 (6): 789–96. doi:10.1111/j.1365-2265.2007.02812.x. PMIDΒ 17437510.
  10. ↑ Martin MM (1969). “Coexisting anterior pituitary and neurohypophyseal insufficiency. A syndrome with diagnostic implication”. Arch. Intern. Med. 123 (4): 409–16. PMIDΒ 4182323.
  11. ↑ Shibata H, Ogishima T, Mitani F, Suzuki H, Murakami M, Saruta T, Ishimura Y (1991). “Regulation of aldosterone synthase cytochrome P-450 in rat adrenals by angiotensin II and potassium”. Endocrinology. 128 (5): 2534–9. doi:10.1210/endo-128-5-2534. PMIDΒ 2019265.
  12. ↑ White PC (1994). “Disorders of aldosterone biosynthesis and action”. N. Engl. J. Med. 331 (4): 250–8. doi:10.1056/NEJM199407283310408. PMIDΒ 8015573.
  13. ↑ Miller KK, Sesmilo G, Schiller A, Schoenfeld D, Burton S, Klibanski A (2001). “Androgen deficiency in women with hypopituitarism”. J. Clin. Endocrinol. Metab. 86 (2): 561–7. doi:10.1210/jcem.86.2.7246. PMIDΒ 11158009.
  14. ↑ Miller KK, Biller BM, Beauregard C, Lipman JG, Jones J, Schoenfeld D, Sherman JC, Swearingen B, Loeffler J, Klibanski A (2006). “Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study”. J. Clin. Endocrinol. Metab. 91 (5): 1683–90. doi:10.1210/jc.2005-2596. PMIDΒ 16478814.
  15. ↑ Soares DV, ConceiΓ§Γ£o FL, Vaisman M (2008). “[Clinical, laboratory and therapeutics aspects of Sheehan’s syndrome]”. Arq Bras Endocrinol Metabol (in Portuguese). 52 (5): 872–8. PMIDΒ 18797595.
  16. ↑ Matsuzaki S, Endo M, Ueda Y, Mimura K, Kakigano A, Egawa-Takata T, Kumasawa K, Yoshino K, Kimura T (2017). “A case of acute Sheehan’s syndrome and literature review: a rare but life-threatening complication of postpartum hemorrhage”. BMC Pregnancy Childbirth. 17 (1): 188. doi:10.1186/s12884-017-1380-y. PMCΒ 5471854. PMIDΒ 28615049.
  17. ↑ Tessnow AH, Wilson JD (2010). “The changing face of Sheehan’s syndrome”. Am. J. Med. Sci. 340 (5): 402–6. doi:10.1097/MAJ.0b013e3181f8c6df. PMIDΒ 20944496.
  18. ↑ Powe CE, Allen M, Puopolo KM, Merewood A, Worden S, Johnson LC, Fleischman A, Welt CK (2010). “Recombinant human prolactin for the treatment of lactation insufficiency”. Clin. Endocrinol. (Oxf). 73 (5): 645–53. doi:10.1111/j.1365-2265.2010.03850.x. PMIDΒ 20718766.

​

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Iqra Qamar M.D.[2].